Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CLVLY CLINUVEL PHARMACEUTICALS LTD SPON ADR EA REP 1 ORD NPV

12.514
+0.813+6.95%
Trading Session 10/03 14:36 ET
High
12.514
Open
12.300
Turnover
3.77K
Low
12.300
Pre Close
11.701
Volume
304.00
Market Cap
618.32M
P/E(TTM)
45.01
52wk High
30.720
Shares
49.41M
P/E(Static)
45.01
52wk Low
9.152
Float Cap
618.32M
Bid/Ask %
0.00%
Historical High
31.380
Shs Float
49.41M
Volume Ratio
0.07
Historical Low
9.152
Dividend TTM
0.017
Div Yield TTM
0.017
P/B
7.58
Dividend LFY
0.14%
Div Yield LFY
0.14%
Turnover Ratio
0.00%
Amplitude
1.83%
Avg Price
12.403
Lot Size
1
Float Cap
618.32M
Bid/Ask %
0.00%
Historical High
31.380
Shs Float
49.41M
Volume Ratio
0.07
Historical Low
9.152
Dividend TTM
0.017
P/B
7.58
Dividend LFY
0.14%
Turnover Ratio
0.00%
Amplitude
1.83%
Avg Price
12.403
Lot Size
1
Price Forecast

No Data

News

Comment

No More
Company Overview More
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
CEO: Dr. Philippe Wolgen, M.B.A.
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...